A phase II trial reported that adding toripalimab, an anti‑PD‑1 antibody, to the FLOT chemotherapy backbone produced encouraging responses in gastric cancer patients with peritoneal metastasis. Investigators highlighted tumor shrinkage and tolerability data that support further evaluation in larger trials. Peritoneal metastasis has poor prognosis; if toripalimab plus FLOT confirms benefit in randomized studies, the regimen could become an option for a high‑need subgroup and influence checkpoint integration across gastrointestinal oncology.